Loading
Hyperfine, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by HC Sponsor LLC, was filed 20 Dec 2022.
Hyperfine, Inc.: what insiders have been doing
Hyperfine, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 7 filings were filed, from 3 insiders.
There is no open-market purchase to report; the filings show 4 sales worth €33k by 2 insiders. Teisseyre Thomas filed the largest sale, €25k, on 25 March 2026.
With 7 filings in twelve months, the company is quieter than the median of 19 filings across the 5,808 companies we follow on the same exchange. Our records for Hyperfine, Inc. go back to 2021, with 9 purchases and 26 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 13.6 m USD and net income of -35.6 m USD.
Typically, a trade is published a median of 1 day after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
64
Thresholds
n/a
Buy Volume
€2M
9 ops. · all time
Sell Volume
€215,543
26 ops. · all time
Who traded when
BuySaleThomas Teisseyre9 sales
Brett Hale2 sales
Since the insiders bought
- +1.9%Entry US$2.06 · Close at T+365 US$2.10
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Hyperfine, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$2.03.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,315 of 23,476 companies
21.3
score / 100
Value6
Quality37
FCF yld-36%
Earn yld-44%
EV/EBITDA·
ROE-97%
Gross mgn50%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.91
Analyst consensus
3 analystsStrong buy
US$1.60Target US$2.03(+124%)US$2.50
Income statement
RevenueUS$13.6M
Gross profitUS$6.8M50% margin
EBITDA-US$36M-265% margin
Net income-US$35.6M-210.8% margin
Valuation
PER (forward)-2.8x
P/Book2.6x
Beta1.46
Balance sheet & cash
Market capUS$96.1M
Total debtUS$248k
Free Cash Flow-US$29.1M
Debt / Equity36%
Profitability & ownership
ROE-97.0%
ROA-38.8%
% insiders4.4%
% institutions22.5%
Last declaration on 25 August 2026
Declarations64 total
7,345 shares@ US$0.8540.0072% mcap8.7% of flowClass A Common StockSEC:0001193125-26-365147:0
7,345 shares@ US$0.8540.0072% mcap17.5% of flowClass A Common StockSEC:0001193125-26-365144:0
330,000 shares0Class A Common StockSEC:0001193125-26-138149:0
330,000 shares0Class A Common StockSEC:0001193125-26-138144:0
750,000 shares0Class A Common StockSEC:0001193125-26-138139:0
24,188 shares@ US$1.2182.5% of flowClass A Common StockSEC:0001193125-26-124362:0
24,188 shares@ US$1.2140.9% of flowClass A Common StockSEC:0001193125-26-124368:0
821 shares@ US$1.11151.2% of flowClass A Common StockSEC:0001193125-26-054433:0
1,405 shares@ US$1.082.1% of flowClass A Common StockSEC:0001193125-25-288507:0
1,151 shares@ US$1.332.1% of flowClass A Common StockSEC:0000950170-25-109724:0
300,000 shares0Class A Common StockSEC:0000950170-25-075386:0
300,000 shares0Class A Common StockSEC:0000950170-25-075380:0
2,776 shares@ US$0.582.3% of flowClass A Common StockSEC:0000950170-25-073807:0
3,238 shares@ US$1.085.4% of flowClass A Common StockSEC:0000950170-25-024316:0
3,237 shares@ US$1.206.0% of flowClass A Common StockSEC:0000950170-25-022627:0
2,800 shares@ US$0.853.7% of flowClass A Common StockSEC:0000950170-24-128110:0
2,746 shares@ US$1.054.2% of flowClass A Common StockSEC:0000950170-24-098132:0
2,753 shares@ US$0.883.6% of flowClass A Common StockSEC:0001209191-24-005657:0
3,230 shares@ US$1.115.4% of flowClass A Common StockSEC:0001209191-24-003440:0
2,655 shares@ US$1.265.0% of flowClass A Common StockSEC:0001209191-23-055911:0
2,785 shares@ US$2.269.4% of flowClass A Common StockSEC:0001209191-23-046315:0
1,729 shares@ US$2.263.4% of flowClass A Common StockSEC:0001209191-23-046313:0
1,735 shares@ US$1.251.9% of flowClass A Common StockSEC:0001209191-23-029926:0
4,635 shares@ US$1.395.6% of flowClass A Common StockSEC:0001209191-23-010632:0
5,613 shares@ US$1.3933.5% of flowClass A Common StockSEC:0001209191-23-010623:0
25 of 64 declarations
About Hyperfine, Inc.
Hyperfine, Inc. (Nasdaq: HYPR) is a U.S.-based medical technology company focused on portable, ultra-low-field brain imaging. Headquartered in Guilford, Connecticut, United States, the company develops and commercializes the Swoop® platform, which it describes as the first FDA-cleared portable MRI system for brain imaging. For French, Belgian, and Swiss investors, Hyperfine sits at the intersection of digital health, diagnostic imaging, and point-of-care care delivery, with a proposition built around accessibility, portability, and the ability to bring brain MRI closer to the patient. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001833769/000119312526114044/hypr-20251231.htm?utm_source=openai))
Hyperfine was founded in 2014 by Dr. Jonathan Rothberg inside the technology incubator 4Catalyzer. The company’s origin story is strongly tied to innovation in applied imaging engineering and to a mission of making MRI more accessible and affordable. Hyperfine later became a public company and is listed on the Nasdaq, where its Class A common stock trades under the symbol HYPR. Its regulatory history has been central to the investment case: the company received initial FDA 510(k) clearance for the Swoop system in 2020 and has since continued to add additional clearances and software upgrades. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001833769/000119312526114044/hypr-20251231.htm?utm_source=openai))
Read moreShow less
The business is centered on the Swoop system and related software and service offerings, most notably the Optive AI™ software suite. These products are intended to improve image quality, clinical workflow, and diagnostic utility while supporting use in sites of care where conventional MRI is difficult to deploy. Hyperfine’s commercial strategy targets hospitals, emergency departments, neurology offices, and international markets, positioning the company as a differentiated alternative to traditional MRI vendors rather than a direct replacement. Its competitive edge lies in portability, lower infrastructure requirements, and the ability to image at the point of care. ([investors.hyperfine.io](https://investors.hyperfine.io/news-releases/news-release-details/hyperfine-announces-fda-clearance-optive-aitm-software/?utm_source=openai))
Geographically, Hyperfine remains primarily U.S.-centric, with core operations in Connecticut and a broader commercial and development footprint that also includes California. At the same time, management has been clearly signaling international expansion. In 2025 and 2026 the company secured CE and UKCA marks for the next-generation Swoop system and Optive AI software, opening access to the European Economic Area and the United Kingdom. The company also disclosed a small number of employees in the UK and Europe, indicating the beginnings of a broader overseas presence. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001833769/000119312526114044/hypr-20251231.htm?utm_source=openai))
Recent milestones are important. In 2025 Hyperfine announced FDA clearance for a next-generation Swoop system powered by Optive AI, followed by the first commercial sales of that system to U.S. hospitals. In early 2026, management highlighted momentum in hospital, neurology office, and international channels, while also presenting clinical data related to stroke detection and neurology use cases. The investment narrative therefore remains a classic medtech commercialization story: proprietary technology, expanding clinical evidence, and regulatory progress on one side, versus execution risk, reimbursement complexity, and the need to convert innovation into sustained revenue growth on the other. ([investors.hyperfine.io](https://investors.hyperfine.io/news-releases/news-release-details/hyperfine-announces-fda-clearance-new-next-generation-swoopr?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
